Sartorius AG · XETR:SRT
Sartorius — Investor Presentation (2022)
24 slides from Sartorius's investor presentation, Nov 29, 2022
Slide 1: This is Sartorius
This is Sartorius Company Presentation | 2022
Slide 2: Partner of Life Science Research and the Biopharmaceutical Industry
Partner of Life Science Research and the Biopharmaceutical Industry Our mission We empower scientists and engineers to simplify and accelerate progress in life science and bioprocessing, enabling the development of new and better therapies and more affordable medicine. Our vision We are a magnet and
Slide 3: Pacesetter for More Than 150 Years
Pacesetter for More Than 150 Years 1870 Florenz Sartorius, a 24-year-old, continues to develop a weighing technology that reduces the time for Evolving from a mechanical balance beam stabilization, substantially accelerating workshop into a leading lab experiments as a result. life science group 192
Slide 4: Sartorius in Brief
Sartorius in Brief 60+ Locations worldwide, headquartered in Göttingen, Germany ~14,000 Employees1 ~€3.45bn Sales revenue2 34.1% EBITDA margin2,3 ~€37.4bn Sartorius AG market capitalization1; ~33% ~41% ~26% listed on the DAX and TecDAX Sales revenue Sales revenue Sales revenue Americas EMEA Asia | P
Slide 5: Strong Company Values Are the Basis of All Our Activities
Strong Company Values Are the Basis of All Our Activities Sustainability Openness Enjoyment Growing profitably and acting Driving change and progress Working in an energetic and responsibly towards all stakeholders internally and externally rewarding environment 5 This is Sartorius
Slide 6: Strategic Focus on the Biopharma Market
Strategic Focus on the Biopharma Market Bioprocess Solutions Division Molecule Cell line and Upstream & development process development downstream production Quality | Testing | Validation Lab Products & Services Division 6 This is Sartorius
Slide 7: Megatrends in Our Target Markets Offer Strong Growth Opportunities
Megatrends in Our Target Markets Offer Strong Growth Opportunities Growing and aging population1 Biologics are gaining importance2 9 billion people by 2050 World population over age 60 in 2050 Sales share of biologics in 2026 >2bn ~37% ~10% CAGR for the biopharma market in 2021–2026 World population
Slide 8: What Are Biopharmaceuticals?
What Are Biopharmaceuticals? Active agent Manufacturing Administration Advantages Biopharmaceuticals Chemical drugs ▪ First-time or improved treatment of serious illnesses, such as cancer, multiple sclerosis, rheumatism ▪ Targets only diseased cells; fewer side effects Small molecules Chemical synth
Slide 9: The Development and Manufacture of Biopharmaceuticals Are Complex
The Development and Manufacture of Biopharmaceuticals Are Complex 9 This is Sartorius
Slide 10: Only One Out of 10,000 New Drug Candidates Reaches the Market
Only One Out of 10,000 New Drug Candidates Reaches the Market Drug Preclinical testing and Clinical Drug discovery further development trials approval 4-5 years 1 year 4-7 years 1-2 years >€2bn ~10% >10 years Average costs of developing Probability of clinical success From drug discovery a successfu
Slide 11: The Consequence: Biotech Medications Are Extremely Expensive
The Consequence: Biotech Medications Are Extremely Expensive HUMIRA® ZOLGENSMA® Annual revenue of ~$20,7 billion; is used to treat rheumatism Currently the world‘s most expensive medical drug; and other inflammatory autoimmune diseases, such as gene therapy used to treat spinal muscular atrophy Croh
Slide 12: Our Ambition: Reduce Costly Trial & Error in Drug Discovery
Our Ambition: Reduce Costly Trial & Error in Drug Discovery Our laboratory tools support researchers ... ... in understanding diseases ... in conducting experiments and evaluating their data ... in identifying the right molecules and developing new medicines 12 This is Sartorius
Slide 13: Our Solution: Technologies to Accelerate Drug Discovery and Development
Our Solution: Technologies to Accelerate Drug Discovery and Development Molecule development Cell line development Identification / Library Lead Candidate Gene Cell line Cell line Cell banking validation screening optimization characterization cloning selection characterization products Key Sartocle
Slide 14: Our Goal: Simplify Manufacturing of Biopharmaceuticals
Our Goal: Simplify Manufacturing of Biopharmaceuticals Our technologies empower engineers in the biopharma industry to ... ... set up robust, flexible and safe processes for industrial production ... reduce setup costs ... enhance product yield 14 This is Sartorius
Slide 15: Our Solution: Innovative Technologies for All Phases of Drug Production
Our Solution: Innovative Technologies for All Phases of Drug Production Products Scalable easy-to-use technologies for the production of biopharmaceuticals and digital tools for biopharma data analytics Application areas Filtration Cell culture technology & media ▪ Biopharmaceutical manufacturing ▪
Slide 16: The Widest Offering of Solutions in the Industry
The Widest Offering of Solutions in the Industry Upstream Production of the desired drug Culture media Seed cultivation Scale-up Production Clarification & preparation centrifugation Downstream Isolation and filling of the desired drug Final Cryo- Sterile Concen- Virus Polishing Chromato- Viral fill
Slide 17: Flexible Production Systems Are Becoming More and More Prevalent
Flexible Production Systems Are Becoming More and More Prevalent Classic stainless steel plants Flexible systems with sterile bags High initial investment outlay Faster setup and lower investment High cleaning effort and expense throughout the entire life cycle Risk of contamination Lower consumptio
Slide 18: Data Analytics Has Huge Potential for the Biopharmaceutical Industry
Data Analytics Has Huge Potential for the Biopharmaceutical Industry Sartorius supports its customers in the digitalization and automation of their processes with its leading software for Data aggregation analysis of bioprocess data. Enhanced process control and robustness Improved product quality P
Slide 19: Leading Market Positions Worldwide in Both Segments
Leading Market Positions Worldwide in Both Segments Fluid Lab Microbiological Lab Fermentation Filtration Purification Pipettes management balances analysis filtration #1 #1 #3 #3 #2 #2 #3 #4 19 This is Sartorius
Slide 20: Acquisitions Strengthen and Differentiate the Sartorius Portfolio
Acquisitions Strengthen and Differentiate the Sartorius Portfolio Essen Life Science assets Intellicyt ViroCyt BioScience from Danaher ALS 2016 2017 2019 2020 2021 2022 kSep Umetrics Biological BIA WaterSep CellGenix Xell Chromatography Albumedix Industries Separations assets from Novasep Acquired t
Slide 21: Sales Revenue Has More Than Doubled Over the Last Five Years
Sales Revenue Has More Than Doubled Over the Last Five Years +49.3% Ø Sales CAGR ~19% ~€3.45bn 45,0 3400 EBITDA Margin1 3200 +14 Pp +30.2% 43,0 3000 41,0 2800 +14.8% 39,0 2600 +13.2% 37,0 2400 +9.3% 35,0 +18.2% 2200 2000 33,0 1800 +16.0% 34.1 +12.6% 31,0 1600 +8.8% 29,0 29.6 1400 27,0 1200 1000 27.1
Slide 22: Sartorius 2025 Ambition and Initiatives
Sartorius 2025 Ambition and Initiatives Strategic initiatives 2025 targets Regional ▪ Participate in strong Chinese market growth ▪ Continue to outperform the important U.S. market ~€5bn Sales revenue Portfolio ▪ Add high-impact innovations, e.g., digital tools ▪ Enhance process development capabili
Slide 23: Substantial Investments in the Expansion of Global Capacities
Substantial Investments in the Expansion of Global Capacities Significant CAPEX ratios CAPEX in millions of €; ratio in % France Finland Aubagne Kajaani, Helsinki China 100 600 Lourdes Beijing USA 90 500 Marlborough 80 70 400 Ann Arbor South Korea 400 60 50 238 226 240 300 Songdo Germany 40 15.2 12.
Slide 24: Thank you.
Thank you.